Leveraging a Multicountry Real-World Data Observatory to Monitor Respiratory Tract Infections and Evaluate Public Health Interventions in Europe
Author(s)
Jasper Deuring1, Esther Dronkers, PhD2, Anke H.W. Bruns, MD PhD3, Maarten van den Berge, MD PhD4, Geert H Groeneveld, MD PhD5, Gerdien Tramper, MD PhD6, Marco Goeijenbier, MD PhD7, Jan Van Der Eijk, MsC2.
1LOGEX B.V., Amsterdam, Netherlands, 2LOGEX BV, Amsterdam, Netherlands, 3UMC Utrecht, utrecht, Netherlands, 4UMC Groningen, Groningen, Netherlands, 5LUMC, Leiden, Netherlands, 6Fransiscus Gasthuis, Rotterdam, Netherlands, 7Spaarne Gasthuis, Hoofddorp, Netherlands.
1LOGEX B.V., Amsterdam, Netherlands, 2LOGEX BV, Amsterdam, Netherlands, 3UMC Utrecht, utrecht, Netherlands, 4UMC Groningen, Groningen, Netherlands, 5LUMC, Leiden, Netherlands, 6Fransiscus Gasthuis, Rotterdam, Netherlands, 7Spaarne Gasthuis, Hoofddorp, Netherlands.
OBJECTIVES: Respiratory tract infections (RTIs), including those caused by respiratory-syncytial virus (RSV), influenza, and SARS-CoV-2, remain a significant burden on healthcare systems across Europe. The LOGEX RTI-Observatory is a pan-European initiative that integrates real-world- clinical data and (microbiology) laboratory data to support evidence-based decision-making in infectious disease management.
METHODS: The RTI-Observatory includes data from multiple hospitals per country across Spain(N=7), UK(N=6), Netherlands(N=7), and Germany(N=45). It captures longitudinal data from more than 25.000 patients since 2019 with a maximum one-quarter lag. The dataset integrates hospital claims, diagnostic codes, and laboratory-confirmed pathogen data, enabling linkage of clinical outcomes with microbiological findings. Health care metrics including hospital admissions, ICU stays, and outpatient visits are calculated.
RESULTS: The observatory has enabled the generation of real-world evidence on the burden and seasonality of RTIs, such as RSV, influenza, and SARS-CoV-2. A project applying the RTI observatory data, the REACH study which has been presented at ESPID 2025, shows the impact of infant RSV health-intervention programs in Spain and the UK. Findings showed a reduction in RSV-related hospitalizations and healthcare utilization in the first season post-implementation, highlighting differences in cost-effectiveness and patient outcomes. Participating hospitals benefit from real-time dashboards, pathogen surveillance, and benchmarking reports that support clinical and operational decision-making. The observatory supports multiple research questions and has already contributed to peer-reviewed publications.
CONCLUSIONS: The LOGEX RTI-Observatory demonstrates the value of integrated, multi-country RWD in monitoring infectious disease trends and evaluating public health interventions. Its scalable infrastructure and rapid data availability make it a platform for different stakeholders like researchers, policymakers, and healthcare providers. The observatory allows to evaluate cross-country clinical impact and cost effectiveness of immunization programs for all kinds or RTI. Acknowledgements Luis Puente Maestuz, Rosa Rodriguez, Victor Cuadrado Martinez, Raul López Martinez, Enrique Maldonado Belmonte , from Gregorio Marañon Hospital, Madrid, Spain
METHODS: The RTI-Observatory includes data from multiple hospitals per country across Spain(N=7), UK(N=6), Netherlands(N=7), and Germany(N=45). It captures longitudinal data from more than 25.000 patients since 2019 with a maximum one-quarter lag. The dataset integrates hospital claims, diagnostic codes, and laboratory-confirmed pathogen data, enabling linkage of clinical outcomes with microbiological findings. Health care metrics including hospital admissions, ICU stays, and outpatient visits are calculated.
RESULTS: The observatory has enabled the generation of real-world evidence on the burden and seasonality of RTIs, such as RSV, influenza, and SARS-CoV-2. A project applying the RTI observatory data, the REACH study which has been presented at ESPID 2025, shows the impact of infant RSV health-intervention programs in Spain and the UK. Findings showed a reduction in RSV-related hospitalizations and healthcare utilization in the first season post-implementation, highlighting differences in cost-effectiveness and patient outcomes. Participating hospitals benefit from real-time dashboards, pathogen surveillance, and benchmarking reports that support clinical and operational decision-making. The observatory supports multiple research questions and has already contributed to peer-reviewed publications.
CONCLUSIONS: The LOGEX RTI-Observatory demonstrates the value of integrated, multi-country RWD in monitoring infectious disease trends and evaluating public health interventions. Its scalable infrastructure and rapid data availability make it a platform for different stakeholders like researchers, policymakers, and healthcare providers. The observatory allows to evaluate cross-country clinical impact and cost effectiveness of immunization programs for all kinds or RTI. Acknowledgements Luis Puente Maestuz, Rosa Rodriguez, Victor Cuadrado Martinez, Raul López Martinez, Enrique Maldonado Belmonte , from Gregorio Marañon Hospital, Madrid, Spain
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
RWD116
Topic
Epidemiology & Public Health, Medical Technologies, Real World Data & Information Systems
Topic Subcategory
Distributed Data & Research Networks
Disease
Infectious Disease (non-vaccine), Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory)